Associated Papers
Well-differentiated systemic mastocytosis: Genetics, mast cell immunophenotypes, and KIT autophosphorylation.
Schornack BJ et al.
The Journal of Allergy and Clinical Immunology, 2025
Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.
Rydz A et al.
International Journal of Molecular Sciences, 2024
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
American Journal of Hematology, 2023
Integrative Genomic Profiling Uncovers Therapeutic Targets of Acral Melanoma in Asian Populations.
Shi Q et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S et al.
International Journal of Molecular Sciences, 2022
Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators.
Fornerod M et al.
Blood Cancer Discovery, 2021
Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology, 2021
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
Nedoszytko B et al.
International Journal of Molecular Sciences, 2021
Systemic Mastocytosis: Molecular Landscape and Implications for Treatment.
Monaldi C et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2021
Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Martelli M et al.
International Journal of Molecular Sciences, 2020
The Role of KIT Mutations in Anaphylaxis.
Coulson E et al.
Current Allergy and Asthma Reports, 2019
Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.
Saglam O et al.
Melanoma Research, 2018
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacological Research, 2018
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
Ma X et al.
Nature, 2018
Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.
Conde-Fernandes I et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology, 2017
Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features.
Molderings GJ
Translational Research : the Journal of Laboratory and Clinical Medicine, 2016
Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.
Ke H et al.
Cell & Bioscience, 2016
KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.
Brahmi M et al.
Bmc Cancer, 2015
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder.
Chatterjee A et al.
Oncotarget, 2015
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.
Arock M et al.
Leukemia, 2015
Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.
Chan EC et al.
The Journal of Allergy and Clinical Immunology, 2014
A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family.
Wang HJ et al.
Clinical and Experimental Dermatology, 2014
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P et al.
Annals of Hematology, 2014
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.
Verstovsek S
European Journal of Haematology, 2013
Somatic D816V KIT mutation in a case of adult-onset familial mastocytosis.
Zanotti R et al.
The Journal of Allergy and Clinical Immunology, 2013
Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics.
Haenisch B et al.
Immunology, 2012
A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis.
Kurtz JE et al.
Sarcoma, 2010
Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment.
Bunimovich O et al.
Cutis, 2009
Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R et al.
The British Journal of Dermatology, 2008
Recent advances in the understanding of mastocytosis: the role of KIT mutations.
Orfao A et al.
British Journal of Haematology, 2007
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
Corless CL et al.
The Journal of Molecular Diagnostics : Jmd, 2006
A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Zhang LY et al.
Leukemia Research, 2006
Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A et al.
Best Practice & Research. Clinical Haematology, 2006
A germline mutation in KIT in familial diffuse cutaneous mastocytosis.
Tang X et al.
Journal of Medical Genetics, 2004